BDSX BIODESIX INC
Services-Medical Laboratories · Nasdaq · SEC CIK 1439725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.2%
TTM net income YoY31.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-18.7%
Net margin-25.7%
FCF margin-18.1%
EBITDA margin-13.4%
Returns
ROE-778.9%
ROA-29.6%
ROIC (approx.)-50.2%
Asset turnover1.15x
Leverage & solvency
Liabilities / assets90.8%
Debt / equity5.76x
Current ratio2.96x
Interest coverage-2.45x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $88.50M | $71.32M | $49.09M | $38.21M | $54.51M |
| R&D expense | $12.00M | $9.56M | $9.99M | $13.10M | $12.79M |
| SG&A expense | $87.55M | $80.45M | $67.39M | $61.46M | $50.52M |
| Operating income | -$27.87M | -$34.50M | -$41.34M | -$50.59M | -$40.94M |
| Interest expense | $7.72M | $8.26M | $9.54M | $8.07M | $4.51M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.27M | -$42.93M | -$52.15M | -$65.45M | -$43.16M |
| EBITDA | -$22.20M | -$28.73M | -$38.01M | -$46.99M | -$37.76M |
| EPS (basic) | -4.67 | -6.64 | -0.64 | -1.55 | -1.58 |
| EPS (diluted) | -4.67 | -6.64 | -0.64 | -1.55 | -1.58 |
| Weighted avg. shares (diluted) | 7.55M | 6.47M | 82.11M | 42.10M | 27.36M |
| Banking | |||||
| Provision for credit losses | $180,000 | $887,000 | $497,000 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $18.99M | $26.33M | $26.37M | $43.17M | $32.80M |
| Receivables | $9.04M | $8.60M | $7.68M | $5.07M | $3.66M |
| Current assets | $32.52M | $39.48M | $39.68M | $53.33M | $43.61M |
| PP&E, net | $24.82M | $27.83M | $27.87M | $5.85M | $4.18M |
| Goodwill | $15.03M | $15.03M | $15.03M | $15.03M | $15.03M |
| Intangibles | $3.88M | $5.87M | $7.91M | $9.80M | $11.62M |
| Total assets | $87.48M | $97.24M | $99.10M | $92.91M | $76.10M |
| Current liabilities | $17.44M | $14.32M | $33.42M | $22.84M | $28.96M |
| Long-term debt | $50.01M | $40.03M | $40.08M | $30.13M | $10.07M |
| Total debt | $50.01M | $40.03M | $40.08M | $30.13M | $10.07M |
| Total liabilities | $89.94M | $76.37M | $94.52M | $72.30M | $56.37M |
| Shareholders' equity | -$2.46M | $20.88M | $4.58M | $20.61M | $19.73M |
| Net debt | $31.02M | $13.69M | $13.71M | -$13.05M | -$22.72M |
| Shares outstanding | 8.25M | 7.27M | 96.24M | 77.61M | 30.79M |
| Cash flow statement | |||||
| Operating cash flow | -$23.27M | -$48.65M | -$22.87M | -$44.97M | -$28.22M |
| Capital expenditure | $259,000 | $3.23M | $22.92M | $3.30M | $2.24M |
| Free cash flow | -$23.53M | -$51.88M | -$45.79M | -$48.27M | -$30.46M |
| Investing cash flow | -$403,000 | -$3.44M | -$23.06M | -$3.53M | -$2.55M |
| Financing cash flow | $16.42M | $52.05M | $29.13M | $58.88M | $1.26M |
| Depreciation & amortization | $5.67M | $5.77M | $3.33M | $3.60M | $3.18M |
| Stock-based compensation | $4.14M | $6.64M | $5.37M | $5.96M | $4.94M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.